All News

The risk of infections with epcoritamab plus R2 appeared to be level off after the first 4 cycles of therapy in the EPCORE FL-1 trial.

At SOHO 2026, David Sallman, MD, explained why ofirnoflast produced responses across MDS subtypes, including in a patient with TP53-mutant disease.

Josef Vymazal, MD, discussed how gadopiclenol’s pharmacokinetics may explain why delayed double-dose imaging outperformed delayed single-dose imaging for detecting brain metastases.

Immunochemotherapy, bispecifics, and next-generation BTK inhibitors dominated discussion of ENKTL, MZL, and Waldenström macroglobulinemia at a SOHO session.

Erica L. Mayer, MD, MPH, discussed the practical questions clinicians must answer as the SERENA-6 early-switch approach with camizestrant enters practice.

DISC-3405 may serve as an adjunctive therapy, not a replacement, for hydroxyurea or interferon, according to Naseema Gangat, MBBS.

DISC-0974 may have utility as monotherapy or in combination with other JAK inhibitors, according to Naseema Gangat, MBBS.

Erica L. Mayer, MD, MPH, explained why oncologists should switch to camizestrant at ESR1 mutation emergence rather than reserve oral SERDs for progression.

Josef Vymazal, MD, discussed a randomized study showing delayed double-dose gadopiclenol significantly improved detection of small brain metastases compared with standard imaging.

Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.

At SOHO 2026, Jasmine Zain, MD, discussed communicating the FDA’s boxed warning for secondary malignancies post–CAR T-cell therapy to patients.

Initial phase 2 SURF302 data show a 79% ORR with 60 mg once-daily oral dabogratinib in FGFR3-altered low-grade intermediate-risk NMIBC.

Combination approvals for revumenib and ziftomenib in relapsed/refractory acute myeloid leukemia may arrive before frontline approvals, according to Eunice Wang, MD.

ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer.

Adding atezolizumab to neoadjuvant chemotherapy did not significantly improve EFS in early TNBC, but node-positive and high-TIL subgroups showed benefit.

Data at SOHO 2026 show how FLT3 inhibitors and venetoclax-based triplets have reshaped induction, consolidation, and maintenance therapy in FLT3-mutated AML.

Josef Vymazal, MD, explained why high-relaxivity contrast agents are critical for detecting small brain metastases, despite weaker agents remaining suitable for other indications.

Although shortages periodically capture national attention when widely used agents such as cisplatin or carboplatin become scarce, the problem extends well beyond any single drug.

The first patient has been dosed in a phase 2 trial evaluating paxalisib plus gemcitabine in children and young adults with recurrent atypical teratoid/rhabdoid tumor.

The interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma.

The FDA has granted accelerated approval to sevabertinib for metastatic non-squamous NSCLC with HER2 TKD activating mutations based on results from the SOHO-01 trial.

Data from the phase 3 DeLLphi-305 trial also showed meaningful improvements in progression-free survival and responses with durvalumab/tarlatamab in SCLC.

In a phase 1/2 study, daraxonrasib produced objective responses in more than 30% of patients with previously treated RAS-mutant NSCLC.

Interim phase 2 data show INBRX-106 plus pembrolizumab nearly doubled response rates and extended survival vs pembrolizumab alone in head and neck cancer.

Lisa Cassileth, MD, FACS, spoke about how mastectomy flap necrosis can delay systemic therapy and radiation, and what teams can do.

The FDA withdrew accelerated approval for adagrasib/cetuximab in KRAS G12C-mutated colorectal cancer after the KRYSTAL-10 trial failed to improve survival.

Herbert Lepor, MD, discussed NYU Langone's 1,000th focal cryotherapy procedure, Andre De Shields' case, and why prostate cancer treatment is at a turning point.

A GDNS protocol did not significantly reduce loss of ASMI compared with usual care during chemoradiotherapy following esophagectomy in esophageal cancer.

The phase 3 TAK-226-3001 trial will evaluate elritercept vs epoetin alfa for anemia in lower-risk myelodysplastic syndromes.

Data from the phase 2 PARADIGM trial may support the use of less toxic, more gentle therapies for patients with acute myeloid leukemia.